Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Taigen Biopharmaceuticals Holdings Ltd.

Headquarters: Taipei, Taiwan
Year Founded: 2001
Status: Public
Industry Sector: HealthTechnology
CEO: Philip Huang, EMBA
Number Of Employees: N/A
Enterprise Value: $220,979,279
PE Ratio: -170.07
Exchange/Ticker 1: TPEx:4157
Exchange/Ticker 2: N/A
Latest Market Cap: $202,172,033

BioCentury | Dec 22, 2017
Financial News

JHL delisting from TPEx

BioCentury | Dec 21, 2017
Financial News

JHL delisting from TPEx

BioCentury | Dec 30, 2016
Company News

China accepts NDA for Ascletis' HCV candidate

BioCentury | Nov 11, 2016
Company News

HEC, TaiGen deal

BioCentury | Jun 20, 2016
Clinical News

Taigexyn nemonoxacin regulatory update

BioCentury | Jun 16, 2016
Company News

CFDA approves TaiGen antibiotic

BioCentury | Apr 26, 2016
Politics & Policy

CFDA names HCV drugs in expedited pathway

BioCentury | Dec 7, 2015
Clinical News

Nemonoxacin: Phase III data

Items per page:
1 - 10 of 26